Loading...

Mallinckrodt

DB:MCD
Snowflake Description

Fair value with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MCD
DB
$778M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Mallinckrodt has significant price volatility in the past 3 months.
MCD Share Price and Events
7 Day Returns
3.8%
DB:MCD
1%
DE Pharmaceuticals
0.3%
DE Market
1 Year Returns
-49.7%
DB:MCD
-29.8%
DE Pharmaceuticals
-11.7%
DE Market
MCD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mallinckrodt (MCD) 3.8% -39.7% -59.8% -49.7% -83.8% -85.5%
DE Pharmaceuticals 1% -4.1% -14.9% -29.8% -23.1% 7.1%
DE Market 0.3% -2.3% -1.1% -11.7% 12.2% 6.1%
1 Year Return vs Industry and Market
  • MCD underperformed the Pharmaceuticals industry which returned -29.8% over the past year.
  • MCD underperformed the Market in Germany which returned -11.7% over the past year.
Price Volatility
MCD
Industry
5yr Volatility vs Market

Value

 Is Mallinckrodt undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Mallinckrodt to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Mallinckrodt.

DB:MCD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 15 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 13.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:MCD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.64 (1 + (1- 19%) (762.94%))
3.407
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (2 * 6.65%)
13.53%

Discounted Cash Flow Calculation for DB:MCD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Mallinckrodt is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:MCD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 13.53%)
2019 776.28 Analyst x4 683.77
2020 856.75 Analyst x6 664.73
2021 889.58 Analyst x4 607.96
2022 787.70 Analyst x3 474.19
2023 778.87 Analyst x3 413.00
2024 773.25 Est @ -0.72% 361.16
2025 769.87 Est @ -0.44% 316.74
2026 768.04 Est @ -0.24% 278.33
2027 767.29 Est @ -0.1% 244.93
2028 767.29 Est @ 0% 215.74
Present value of next 10 years cash flows $4,260.54
DB:MCD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $767.29 × (1 + 0.23%) ÷ (13.53% – 0.23%)
$5,782.28
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,782.28 ÷ (1 + 13.53%)10
$1,625.81
DB:MCD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $4,260.54 + $1,625.81
$5,886.35
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $5,886.35 / 83.81
$70.23
DB:MCD Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:MCD represents 0.88362x of NYSE:MNK
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88362x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 70.23 x 0.88362
€62.06
Value per share (EUR) From above. €62.06
Current discount Discount to share price of €8.20
= -1 x (€8.20 - €62.06) / €62.06
86.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Mallinckrodt is available for.
Intrinsic value
>50%
Share price is €8.2 vs Future cash flow value of €62.06
Current Discount Checks
For Mallinckrodt to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Mallinckrodt's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Mallinckrodt's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mallinckrodt's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mallinckrodt's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MCD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-29) in USD $-41.34
NYSE:MNK Share Price ** NYSE (2019-06-17) in USD $9.28
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.7x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.7x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mallinckrodt.

DB:MCD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:MNK Share Price ÷ EPS (both in USD)

= 9.28 ÷ -41.34

-0.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mallinckrodt is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • Mallinckrodt is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Mallinckrodt's expected growth come at a high price?
Raw Data
DB:MCD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts
63.7%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.99x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.47x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mallinckrodt, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mallinckrodt's assets?
Raw Data
DB:MCD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-29) in USD $36.56
NYSE:MNK Share Price * NYSE (2019-06-17) in USD $9.28
Germany Pharmaceuticals Industry PB Ratio Median Figure of 8 Publicly-Listed Pharmaceuticals Companies 1.76x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.76x
DB:MCD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:MNK Share Price ÷ Book Value per Share (both in USD)

= 9.28 ÷ 36.56

0.25x

* Primary Listing of Mallinckrodt.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mallinckrodt is good value based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Mallinckrodt's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Mallinckrodt has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Mallinckrodt expected to perform in the next 1 to 3 years based on estimates from 15 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mallinckrodt expected to grow at an attractive rate?
  • Mallinckrodt's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Mallinckrodt's earnings growth is expected to exceed the Germany market average.
  • Mallinckrodt's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:MCD Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:MCD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts 63.7%
DB:MCD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts -4.6%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MCD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MCD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 2,742 802 5 10
2022-12-31 2,746 776 63 12
2021-12-31 2,805 699 13
2020-12-31 3,100 871 162 14
2019-12-31 3,229 932 15
DB:MCD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-29 3,251 812 -3,446
2018-12-28 3,216 666 -3,622
2018-09-28 3,488 760 1,799
2018-06-29 3,449 767 1,749
2018-03-30 3,417 843 1,795
2017-12-29 3,222 727 1,771
2017-09-29 2,591 358 -150
2017-06-30 2,877 322 -93
2017-03-31 3,144 456 65
2016-12-30 3,400 782 208
2016-09-30 3,381 1,185 489
2016-06-24 3,686 1,332 522

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mallinckrodt's earnings are expected to grow significantly at over 20% yearly.
  • Mallinckrodt's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MCD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below

All data from Mallinckrodt Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MCD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.76 -0.76 -0.76 1.00
2022-12-31 -0.84 -0.84 -0.84 1.00
2021-12-31 -2.70 -1.57 -3.83 2.00
2020-12-31 1.87 5.76 -0.50 4.00
2019-12-31 3.62 6.06 1.84 3.00
DB:MCD Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-29 -41.34
2018-12-28 -43.12
2018-09-28 20.87
2018-06-29 19.52
2018-03-30 19.22
2017-12-29 18.13
2017-09-29 -1.49
2017-06-30 -0.90
2017-03-31 0.61
2016-12-30 1.93
2016-09-30 4.42
2016-06-24 4.62

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Mallinckrodt is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Mallinckrodt's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mallinckrodt has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Mallinckrodt performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mallinckrodt's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mallinckrodt does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Mallinckrodt's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mallinckrodt's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Mallinckrodt's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mallinckrodt Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MCD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-29 3,250.90 -3,445.80 880.30 364.40
2018-12-28 3,215.60 -3,621.90 872.90 361.10
2018-09-28 3,487.90 1,798.60 851.70 374.50
2018-06-29 3,448.50 1,748.70 943.20 342.90
2018-03-30 3,416.90 1,795.20 967.00 313.90
2017-12-29 3,221.60 1,771.20 972.90 276.90
2017-09-29 2,590.60 -150.20 1,065.70 210.40
2017-06-30 2,877.20 -93.30 1,074.60 231.40
2017-03-31 3,143.70 65.00 1,083.90 253.90
2016-12-30 3,399.50 208.40 1,077.60 266.90
2016-09-30 3,380.80 489.00 928.90 261.20
2016-06-24 3,685.80 521.70 1,021.20 212.80
2016-03-25 3,592.50 381.20 1,036.00 196.60
2015-12-25 3,493.50 335.20 1,061.80 196.00
2015-09-25 2,923.10 234.60 897.40 203.30
2015-06-26 2,795.40 38.30 846.70 211.00
2015-03-27 2,571.20 -41.20 819.00 193.80
2014-12-26 2,310.00 -103.80 731.30 177.20
2014-09-26 1,650.30 -22.00 519.40 140.50
2014-06-27 2,296.30 65.00 685.60 166.40
2014-03-28 2,213.20 61.60 624.20 168.50
2013-12-27 2,240.70 84.40 609.30 166.30
2013-09-27 1,712.30 8.20 495.90 157.90
2013-06-28 2,172.40 53.90 614.80 159.00
2013-03-29 2,118.70 116.70 585.10 149.40
2012-12-28 2,056.50 124.50 568.40 145.40
2012-09-28 2,056.20 141.30 551.70 144.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mallinckrodt has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mallinckrodt has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mallinckrodt improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mallinckrodt's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mallinckrodt has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Mallinckrodt's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mallinckrodt's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mallinckrodt is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mallinckrodt's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Mallinckrodt's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mallinckrodt Company Filings, last reported 2 months ago.

DB:MCD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-29 3,053.90 5,934.10 225.80
2018-12-28 2,887.30 6,091.60 348.90
2018-09-28 6,603.60 6,190.70 290.70
2018-06-29 6,474.40 6,357.30 235.70
2018-03-30 6,461.30 6,813.60 511.90
2017-12-29 6,522.00 6,734.60 1,260.90
2017-09-29 5,113.00 5,835.60 373.40
2017-06-30 5,096.00 5,857.90 335.20
2017-03-31 5,114.20 5,944.80 264.70
2016-12-30 4,984.30 6,152.00 353.10
2016-09-30 5,270.70 6,045.00 280.50
2016-06-24 5,208.80 6,300.70 521.90
2016-03-25 5,097.90 6,431.20 341.40
2015-12-25 5,192.60 6,431.50 521.90
2015-09-25 5,311.20 6,496.30 365.90
2015-06-26 5,298.10 5,355.70 225.30
2015-03-27 5,186.10 3,988.70 1,053.50
2014-12-26 5,071.80 3,965.10 899.00
2014-09-26 4,958.00 3,895.20 707.80
2014-06-27 1,328.40 2,215.70 327.90
2014-03-28 1,338.40 2,215.90 334.90
2013-12-27 1,309.30 919.40 287.80
2013-09-27 1,255.60 919.80 275.50
2013-06-28 1,158.00 919.90 180.40
2013-03-29 2,139.40 10.70
2012-12-28 2,113.70 9.90
2012-09-28 1,891.90 10.20
  • Mallinckrodt's level of debt (191.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (165.6% vs 191.1% today).
  • Debt is not well covered by operating cash flow (13.9%, less than 20% of total debt).
  • Mallinckrodt is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess Mallinckrodt's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mallinckrodt has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Mallinckrodt's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mallinckrodt dividends. Estimated to be 0% next year.
If you bought €2,000 of Mallinckrodt shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mallinckrodt's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mallinckrodt's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MCD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MCD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mallinckrodt has not reported any payouts.
  • Unable to verify if Mallinckrodt's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mallinckrodt's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mallinckrodt has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Mallinckrodt's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Mallinckrodt's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mallinckrodt afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mallinckrodt has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Mallinckrodt's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Trudeau
COMPENSATION $14,044,012
AGE 57
TENURE AS CEO 6 years
CEO Bio

Mr. Mark Christopher Trudeau has been the Chief Executive Officer and President at Mallinckrodt Public Ltd Company since June 2013. Mr. Trudeau was joined Covidien plc as Senior Vice President and President of Pharmaceuticals Segment in February 1, 2012. He was joined Covidien from Bayer HealthCare Pharmaceuticals LLC USA, the U.S. healthcare business of Bayer AG, where he served as Chief Executive Officer. He simultaneously served as President of Bayer HealthCare Pharmaceuticals, the U.S. organization of Bayer’s global pharmaceuticals business. He served as an Interim President of the global specialty medicine business unit from January 2010 to August 2010. Prior to joining Bayer in 2009, Mr. Trudeau headed the Immunoscience Division at Bristol-Myers Squibb. During his 10-plus years at Bristol-Myers Squibb, he served in multiple senior roles, including President of the Asia/Pacific region, President and General Manager of Canada and General Manager/Managing Director in the United Kingdom. He has experience as a public company executive officer and director, along with a record of executive leadership and global business expertise in many areas including strategy, operations and management. He was also with Abbott Laboratories, serving in a variety of executive positions, from 1988 to 1998. He served as President Commissioner of PT Taisho Pharmaceutical Indonesia Tbk. Mr. Trudeau has been a Director of Mallinckrodt Public Ltd Company since June 17, 2013 and TE Connectivity Ltd since March 2016. He has been a Director at Donald Danforth Plant Science Center since December 2013. Mr. Trudeau holds a Bachelor’s degree in chemical engineering and M.B.A., both from the University of Michigan.

CEO Compensation
  • Mark's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Mark's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Mallinckrodt management team in years:

1.3
Average Tenure
54
Average Age
  • The average tenure for the Mallinckrodt management team is less than 2 years, this suggests a new team.
Management Team

Mark Trudeau

TITLE
President
COMPENSATION
$14M
AGE
57
TENURE
6 yrs

Frank Scholz

TITLE
Executive VP and Chief Operations & Digital Innovation Officer
COMPENSATION
$3M
AGE
49
TENURE
2.8 yrs

Steven Romano

TITLE
Executive VP & Chief Scientific Officer
COMPENSATION
$4M
AGE
59

Mark Casey

TITLE
General Counsel
COMPENSATION
$3M
AGE
54
TENURE
1.3 yrs

Matthew Harbaugh

TITLE
Executive VP & President of Specialty Generics
COMPENSATION
$4M
AGE
48
TENURE
0.5 yrs

George Kegler

TITLE
Executive Vice President
COMPENSATION
$1M
AGE
62
TENURE
0.3 yrs

Bryan Reasons

TITLE
Chief Financial Officer
AGE
51
TENURE
0.3 yrs

Daniel Speciale

TITLE
Vice President of Investor Relations & IRO
TENURE
1.4 yrs

Karen Sheehy

TITLE
Chief Compliance Officer
AGE
56
TENURE
2.4 yrs

Dagmar Rosa-Björkeson

TITLE
Chief Strategy & Corporate Development Officer
AGE
54
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Mallinckrodt board of directors in years:

3.9
Average Tenure
62
Average Age
  • The tenure for the Mallinckrodt board of directors is about average.
Board of Directors

Angus Russell

TITLE
Non Executive Chairman
COMPENSATION
$552K
AGE
62
TENURE
1.1 yrs

Mark Trudeau

TITLE
President
COMPENSATION
$14M
AGE
57
TENURE
6 yrs

David Carlucci

TITLE
Independent Director
COMPENSATION
$415K
AGE
63
TENURE
6 yrs

Marty Carroll

TITLE
Independent Director
COMPENSATION
$420K
AGE
69
TENURE
6 yrs

JoAnn Reed

TITLE
Independent Director
COMPENSATION
$420K
AGE
62
TENURE
6 yrs

Kneeland Youngblood

TITLE
Independent Director
COMPENSATION
$405K
AGE
63
TENURE
6 yrs

David Norton

TITLE
Director
COMPENSATION
$411K
AGE
67
TENURE
1.8 yrs

Anne Whitaker

TITLE
Independent Director
COMPENSATION
$360K
AGE
51
TENURE
1.1 yrs

Paul Rutherford Carter

TITLE
Independent Director
COMPENSATION
$360K
AGE
57
TENURE
1.1 yrs

Jörg Gerlach

TITLE
Member of Scientific Advisory Council
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Mallinckrodt insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Jun 19 Buy Bryan Reasons Individual 07. Jun 19 07. Jun 19 5,400 €7.90 €42,674
31. May 19 Buy Mark Trudeau Individual 30. May 19 30. May 19 2,000 €8.32 €16,640
10. May 19 Buy Mark Trudeau Individual 09. May 19 09. May 19 1,000 €14.54 €14,536
06. Mar 19 Buy Mark Trudeau Individual 05. Mar 19 05. Mar 19 1,000 €20.05 €20,045
11. Dec 18 Buy Mark Trudeau Individual 10. Dec 18 10. Dec 18 1,000 €17.75 €17,752
X
Management checks
We assess Mallinckrodt's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mallinckrodt has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. It has collaboration with the Washington University School of Medicine in St. Louis. The company was founded in 1867 and is based in Staines-Upon-Thames, the United Kingdom.

Details
Name: Mallinckrodt plc
MCD
Exchange: DB
Founded: 1867
$692,390,660
83,813,820
Website: http://www.mallinckrodt.com
Address: Mallinckrodt plc
3 Lotus Park,
The Causeway,
Staines-Upon-Thames,
Surrey, TW18 3AG,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE MNK New Ordinary Shares New York Stock Exchange US USD 17. Jun 2013
DB MCD New Ordinary Shares Deutsche Boerse AG DE EUR 17. Jun 2013
Number of employees
Current staff
Staff numbers
3,700
Mallinckrodt employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/17 21:34
End of day share price update: 2019/06/17 00:00
Last estimates confirmation: 2019/06/17
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/29
Last annual earnings reported: 2018/12/28


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.